Surface Oncology, Inc.
Anti-IL-27 antibodies and uses thereof
Last updated:
Abstract:
The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.
Status:
Grant
Type:
Utility
Filling date:
22 Mar 2019
Issue date:
17 May 2022